Die INCA-Studie (Impact of NOD2 genotype-guided antibiotic prevention on survival in patients with liver cirrhosis and ascites): Präzise medizinische Therapie der Patienten mit Leberzirrhose und Aszites

M. Casper; B. Appenrodt; F. Grünhage; F. Lammert

doi:10.1055/s-0041-103525

Zeitschrift für Gastroenterologie, Table of Contents

Z Gastroenterol 2015; 53(11): 1350-1352
DOI: 10.1055/s-0041-103525

Aktuelle Studien

Die INCA-Studie (Impact of NOD2 genotype-guided antibiotic prevention on survival in patients with liver cirrhosis and ascites): Präzise medizinische Therapie der Patienten mit Leberzirrhose und Aszites

The INCA trial (impact of NOD2 genotype-guided antibiotic prevention on survival in patients with liver cirrhosis and ascites): Precision medicine for patients with liver cirrhosis and ascites

Authors

M. Casper
B. Appenrodt
F. Grünhage
F. Lammert

Abstract

Schlüsselwörter

Aszites - klinische Studien - Leberzirrhose

Key words

ascites - clinical trials - liver cirrhosis

Full Text

References

Literatur
1 Appenrodt B, Grünhage F, Gentemann MG et al. Nucleotide-binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis. Hepatology 2010; 51: 1327-1333
2 Karlsen TH, Lammert F, Thompson RJ. Genetics of liver disease: From pathophysiology to clinical practice. J Hepatol 2015; 62: S6-S14
3 Jameson JL, Longo DL. Precision medicine – personalized, problematic and promising. N Engl J Med 2015; 372: 229-2234